Literature DB >> 8402626

Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.

R Henriksen1, K Funa, E Wilander, T Bäckström, M Ridderheim, K Oberg.   

Abstract

The expression of platelet-derived growth factor (PDGF), PDGF-alpha receptor (PDGFR alpha) and PDGF-beta receptor (PDGFR beta) was studied in normal ovaries and ovarian neoplasms by immunohistochemical analysis. PDGF was detected in tumor cells in 33 of 45 malignant tumor samples but in none of 20 benign tumors (P < 0.001) or 11 normal ovaries (P < 0.001). In borderline tumors, 4 of 7 tissues stained positive in tumor cells. PDGFR alpha was detected in tumor cells in 16 of 45 malignant tumors, while no epithelial staining was found in 16 benign tumors (P = 0.002) or in 10 normal ovaries (P = 0.023). In 1 of 7 borderline neoplasms, tumor cells expressed PDGFR alpha. Neither normal epithelium nor tumor cells stained positive with antibodies against PDGFR beta. Patients with ovarian cancer and PDGFR alpha-positive tumor cells demonstrated an overall shorter survival compared to those who had negatively stained tumors (P < 0.005). A similar correlation was found in patients having stage III ovarian cancer (P < 0.01), which further supports an independent role for PDGFR alpha as a prognostic factor. Thus, the concomitant expression of PDGF and PDGFR alpha in tumor cells is related to progression of malignant ovarian tumors, indicating a functional role of PDGF via autocrine growth stimulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8402626

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

Review 2.  Targeted therapies for gynecologic malignancies.

Authors:  Johnny Hyde; D Scott McMeekin
Journal:  Curr Treat Options Oncol       Date:  2005-03

Review 3.  Imatinib mesylate and its potential implications for gynecologic cancers.

Authors:  Holly Dushkin; Russell J Schilder
Journal:  Curr Treat Options Oncol       Date:  2005-03

4.  Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.

Authors:  Ju-Won Roh; Jie Huang; Wei Hu; XiaoYun Yang; Nicholas B Jennings; Vasudha Sehgal; Bo Hwa Sohn; Hee Dong Han; Sun Joo Lee; Duangmani Thanapprapasr; Justin Bottsford-Miller; Behrouz Zand; Heather J Dalton; Rebecca A Previs; Ashley N Davis; Koji Matsuo; Ju-Seog Lee; Prahlad Ram; Robert L Coleman; Anil K Sood
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

Review 5.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

6.  Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

Authors:  E Buchdunger; J Zimmermann; H Mett; T Meyer; M Müller; U Regenass; N B Lydon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

Review 7.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

8.  Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.

Authors:  Samir D Undevia; Nicholas J Vogelzang; Ann M Mauer; Linda Janisch; Sridhar Mani; Mark J Ratain
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

9.  Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas.

Authors:  Jan Friederichs; Claus W H von Weyhern; Robert Rosenberg; Dietrich Doll; Raymonde Busch; Florian Lordick; Jörg Rüdiger Siewert; Mario Sarbia
Journal:  Langenbecks Arch Surg       Date:  2009-03-12       Impact factor: 3.445

10.  Antivascular therapy for epithelial ovarian cancer.

Authors:  Francois P Duhoux; Jean-Pascal Machiels
Journal:  J Oncol       Date:  2009-12-23       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.